.... This multicenter study aimed to determine whether LI-RADS categorization can offer additional post-surgical prognostic value for intrahepatic cholangiocarcinoma (ICCA) when used in conjunction with the American Joint Committee on Cancer (AJCC) guidelines. Methods: Patients with high risk for hepatocellular...

...Naoshi Nishida; Masatoshi Kudo Background: Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However...

...Joo-Hyun Park; Jung Yong Hong; Kyungdo Han Introduction: The association between smoking cessation and intrahepatic and extrahepatic cholangiocarcinoma (iCCA and eCCA) risk is unclear. Furthermore, the association in individuals with preexisting risk factors is unknown. We aimed to investigate...

... Verset; Eric Trepo; Aziz Zaanan; Marianne Ziol; Massih Ningarhari; Julien Calderaro; Julien Edeline; Jean-Charles Nault Backgrounds and Aims: Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum...

...Sungeun Park; Youngeun Lee; Haeryoung Kim; Mi Hye Yu; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Jeong Min Lee Introduction: Small-duct (SD) and large-duct (LD) subtypes of cholangiocarcinoma have been investigated for their prognostic factors. This study aimed to evaluate the diagnostic value of liver...

... design) explored two GNS561 dosing schedules: one single oral intake 3 times a week (Q3W) and twice daily (BID) continuous oral administration in patients with advanced hepatocellular carcinoma, cholangiocarcinoma, and pancreatic adenocarcinoma or colorectal adenocarcinomas with liver metastasis...

...María Gutiérrez-Larrañaga; Elena González-López; Adriel Roa-Bautista; Pedro M. Rodrigues; Álvaro Díaz-González; Jesus M. Banales; Marcos López-Hoyos; Alvaro Santos-Laso; Javier Crespo Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignant tumors with dismal prognosis...

...Seo Hee Choi; Chai Hong Rim; In-Soo Shin; Won Sup Yoon; Woong Sub Koom; Jinsil Seong Introduction: The benefits of adjuvant radiotherapy (ART) for extrahepatic cholangiocarcinoma are uncertain largely because existing publications lack clear comparisons between ART and non-ART arms. Methods: PubMed...

...Qian Yu; Chenyu Liu; Anjana Pillai; Osman Ahmed Purpose: Both external beam radiation therapy (EBRT) and selective-internal radiation therapy (SIRT) are implemented to treat unresectable intrahepatic cholangiocarcinoma (iCCA). The present study aimed to evaluate the efficacy of EBRT and SIRT...

...Jan Bednarsch; Jakob Kather; Xiuxiang Tan; Shivan Sivakumar; Claudio Cacchi; Georg Wiltberger; Zoltan Czigany; Florian Ulmer; Ulf Peter Neumann; Lara Rosaline Heij Introduction: Perihilar cholangiocarcinoma (pCCA) is a biliary tract cancer with a dismal prognosis, with surgery being the only chance...

...Damiano Gentile; Matteo Donadon; Ana Lleo; Alessio Aghemo; Massimo Roncalli; Luca di Tommaso; Guido Torzilli Background: Hepatocholangiocarcinoma (HCC-CC) is a rare liver malignancy that contains features of both hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC). Three...

...Tomoki Ebata; Giorgio Ercolani; Domenico Alvaro; Dario Ribero; Luca Di Tommaso; Juan W. Valle Background: Cholangiocarcinomas (CC) as well as gallbladder cancers are relatively rare and intractable diseases. Clinical, pathological, and epidemiological studies on these tumors have been under...

... on a cirrhotic background, contrast-enhanced ultrasonography (CEUS) was included in the American diagnostic algorithm for HCC in 2005. However, its role has been questioned because of the possibility of misdiagnosis of cholangiocarcinoma. The present review aims to describe the advantages and disadvantages...